Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2016: Differential Cancer Macquarie Cancer effects of MAPK inhibition on $2,078.50 04/04/2017 24 Macquarie University 2109 Australia University Research immune activity determine Scheme melanoma response: ID1123911. Ref: CA-G1516/78 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase II Priority Driven clinical trial of the PARP Collaborative Cancer University of inhibitor, olaparib, in HR- The University of Cancer $300,000.00 10/04/2017 36 2006 Australia Sydney deficient advanced breast Sydney Research and ovarian cancer in Scheme women without inherited BRCA1 or BRCA2 mutations: ID1128740. Ref: CA-G1516/71 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: AUTO-CHECK Priority Driven study: Molecular Collaborative Cancer Australian National determinants of autoimmunity Cancer $574,009.00 10/04/2017 36 Acton 2601 Australia University and immune related adverse Research events in advanced cancer Scheme patients treated with immune checkpoint inhibitors: ID1130330. Ref: CA-G1516/74 Priority Driven Collaborative Priority Driven Cancer Research Scheme Collaborative (PDCCRS) 2016: High Precision Cancer University of The University of Cancer Radiotherapy: Dual Cardiac $597,325.50 28/04/2017 36 2006 Australia Sydney Sydney Research and Respiratory Motion Scheme Management: ID1123068. Ref: CA-G1516/55 Priority Driven Collaborative Cancer Research Scheme Priority Driven (PDCCRS) 2016: The SPAR Collaborative Cancer University of Trial: a randomised The University of Cancer $148,857.00 02/06/2017 36 2006 Australia Sydney phase 2 trial of Sydney Research simvastatin with preoperative Scheme chemoradiation for rectal cancer. ID1125958. Ref:
Cancer Australia Priority Driven Collaborative Cancer Research Scheme Macquarie University Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Differential effects of MAPK inhibition on immune activity determine melanoma response: ID1123911. Ref: CA-G1516/78 $2,078.50 04/04/2017 24 Macquarie University 2109 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations: ID1128740. Ref: CA-G1516/71 $300,000.00 10/04/2017 36 The University of Sydney 2006 Cancer Australia Priority Driven Collaborative Cancer Research Scheme Australian National University Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: AUTO-CHECK study: Molecular determinants of autoimmunity and immune related adverse events in advanced cancer patients treated with immune checkpoint inhibitors: ID1130330. Ref: CA-G1516/74 $574,009.00 10/04/2017 36 Acton 2601 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: High Precision Radiotherapy: Dual Cardiac and Respiratory Motion Management: ID1123068. Ref: CA-G1516/55 $597,325.50 28/04/2017 36 The University of Sydney 2006 Cancer Australia Priority Driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2016: The SPAR Trial: a randomised phase 2 trial of simvastatin with preoperative chemoradiation for rectal cancer. ID1125958. Ref: $148,857.00 02/06/2017 36 The University of Sydney 2006
grants_reporting_20170703_3.docx